Development of quantitative detection assays for CYR61 as a new marker for benign prostatic hyperplasia

Journal of Biomolecular Screening

Volumn 8, Issue 6, 2003, Pages 701-711

  Sakamoto, Shinji ^a   Yokoyama, Masahiro ^a   Prakash, Kulkarni ^b   Tsuruha, Jun Ichiro ^a   Masamoto, Satoshi ^a   Getzenberg, Robert H ^c   Kakehi, Yoshiyuki ^d  

^a JT Inc   (Japan)

^b Gene Logic Inc   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d KAGAWA UNIVERSITY   (Japan)

Author keywords

bDNA; CYR61; Prostate; Sandwich ELISA; Suppressor

Indexed keywords

BIOLOGICAL MARKER; CYSTEINE RICH PROTEIN 61; MESSENGER RNA; CYR61 PROTEIN, HUMAN; DNA; IMMEDIATE EARLY PROTEIN; SIGNAL PEPTIDE; TUMOR MARKER;

ANIMAL CELL; ARTICLE; BIOTECHNOLOGY; CONTROLLED STUDY; DIAGNOSTIC TEST; DISEASE ACTIVITY; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; CATTLE; CELL LINE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; METHODOLOGY; SERUM; STANDARD;

ANIMALS; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; CATTLE; CELL LINE; DNA; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PROSTATIC HYPERPLASIA; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SERUM; TUMOR MARKERS, BIOLOGICAL;

EID: 2542431849     PISSN: 10870571     EISSN: None     Source Type: Journal    
DOI: 10.1177/1087057103259159     Document Type: Article

References (30)

1. Walsh PC: Human benign prostatic hyperplasia: etiological considerations. Prog Clin Biol Res 1984;145:1-25.
2. Caprino L: Drugs for the treatment of benign prostatic hypertrophy. Minerva Urol Nefrol 2000;52:87-92.
3. Berthon P, Waller AS, Villette JM, Loridon L, Cussenot O, Maitland NJ: Androgens are not a direct requirement for the proliferation of human prostatic epithelium in vitro. Int J Cancer 1997;73:910-916.
4. Bartsch G, Rittmaster RS, Klocker H: Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000;37:367-380.
5. Wong YC, Wang YZ: Growth factors and epithelial-stromal interactions in prostate cancer development. Int Rev Cytol 2000;199:65-116.
6. Ziada A, Rosenblum M, Crawford ED: Benign prostatic hyperplasia: an overview. Urology 1999;53(Suppl. 3a):1-6.
7. De Marzo AM, Coffey DS, Nelson WG: New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia. Urology 1999;53(Suppl. 3a):29-42.
8. Cabelin MA, Te AE, Kaplan SA: Benign prostatic hyperplasia: challenges for the new millennium. Curr Opin Urol 2000;10:301-306.
9. Ghafar MA, Puchner PJ, Anastasiadis AG, Cabelin MA, Buttyan R: Does the prostatic vascular system contribute to the development of benign prostatic hyperplasia? Curr Urol Rep 2002;3:292-296.
10. Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, et al: Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci USA 2002;99:7598-7603.
11. Brigstock DR: The connective tissue growth factor/cysteine-rich 61/ nephroblastoma overexpressed (CCN) family. Endocr Rev 1999;20:189-206.
12. Perbal B: NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol Pathol 2001;54:57-79.
13. Kireeva ML, MOFE, Yang GP, Lau LF: CYR61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol 1996;16:1326-1334.
14. Schutze N, Lechner A, Groll C, Siggelkow H, Hufner M, Kohrle J, et al: The human analog of murine cysteine rich protein 61 [correction of 16] is a 1alpha,25-dihydroxyvitamin D3 responsive immediate early gene in human fetal osteoblasts: regulation by cytokines, growth factors, and serum. Endocrinology 1998;139:1761-1770.
15. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF: CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998;95:6355-6360.
16. Kolesnikova TV, Lau LF: Human CYR61-mediated enhancement of bFGF-induced DNA synthesis in human umbilical vein endothelial cells. Oncogene 1998;16:747-754.
17. Giancotti FG, Ruoslahti E: Integrin signaling. Science 1999;285:1028-1032.
18. Sampath D, Winneker RC, Zhang Z: CYR61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human breast cancer. Endocrinology 2001;142:2540-2548.
19. Tsai MS, Hornby AE, Lakins J, Lupu R: Expression and function of CYR61, an angiogenic factor, in breast cancer cell lines and tumor biopsies. Cancer Res 2000;60:5603-5607.
20. Hilfiker A, Hilfiker-Kleiner D, Fuchs M, Kaminski K, Lichtenberg A, Rothkotter HJ, et al: Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II. Circulation 2002;106:254-260.
21. Schober JM, Chen N, Grzeszkiewicz TM, Jovanovic I, Emeson EE, Ugarova TP, et al: Identification of integrin alpha(M)beta(2) as an adhesion receptor on peripheral blood monocytes for CYR61 (CCN1) and connective tissue growth factor (CCN2): Immediate-early gene products expressed in atherosclerotic lesions. Blood 2002;99:4457-4465.
22. Wu KJ, Yee A, Zhu NL, Gordon EM, Hall FL: Characterization of differential gene expression in monkey arterial neointima following balloon catheter injury. Int J Mol Med 2000;6:433-440.
23. Pendurthi UR, Allen KE, Ezban M, Rao LV: Factor VIIa and thrombin induce the expression of CYR61 and connective tissue growth factor, extracellular matrix signaling proteins that could act as possible downstream mediators in factor VIIa • tissue factor-induced signal transduction. J Biol Chem 2000;275:14632-14641.
24. Xie D, Miller CW, O'Kelly J, Nakachi K, Sakashita A, Said JW, et al: Breast cancer: CYR61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 2001;276:14187-14194.
25. Xie D, Nakachi K, Wang H, Elashoff R, Koeffler HP: Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features. Cancer Res 2001;61:8917-8923.
26. Prostate enlargement: benign prostatic hyperplasia by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health [Online]. Retrieved from http://kidney.niddk.nih.gov/ kudiseases/pubs/prostateenlargement/index.htm
27. QuantiGene products: principle of QuantiGene bDNA assay [Online], Retrieved from http://www.genospectra.com/prod_QP.html
28. Warrior U, Fan Y, David CA, Wilkins JA, McKeegan EM, Kofron JL, et al: Application of QuantiGene nucleic acid quantification technology for high throughput screening. J Biomol Screen 2000;5:343-352.
29. Shyamala V, Khoja H, Anderson ML, Wang J, Cen H, Kavanaugh WM: High-throughput screening for ligand-induced c-fos mRNA expression by branched DNA assay in Chinese hamster ovary cells. Anal Biochem 1999;266:140-147.
30. Pilarsky CP, Schmidt U, Eissrich C, Stade J, Froschermaier SE, Haase M, et al: Expression of the extracellular matrix signaling molecule CYR61 is downregulated in prostate cancer. Prostate 1998;36:85-91.